1314894-25-1

Basic information

• Product Name: tert-butyl [(1R,2R)-2-[({4-[6-(difluoromethoxy)pyrazolo[1,5-a]pyrimidin-3-yl]-5-ethylthiophen-2-yl}carbonyl)amino]-3,3-difluorocyclohexyl]carbamate
• Synonyms: tert-butyl [(1R,2R)-2-[({4-[6-(difluoromethoxy)pyrazolo[1,5-a]pyrimidin-3-yl]-5-ethylthiophen-2-yl}carbonyl)amino]-3,3-difluorocyclohexyl]carbamate
• CAS NO: 1314894-25-1
• Molecular Weight: 571.596
• Mol File: 1314894-25-1.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: tert-butyl [(1R,2R)-2-[({4-[6-(difluoromethoxy)pyrazolo[1,5-a]pyrimidin-3-yl]-5-ethylthiophen-2-yl}carbonyl)amino]-3,3-difluorocyclohexyl]carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl [(1R,2R)-2-[({4-[6-(difluoromethoxy)pyrazolo[1,5-a]pyrimidin-3-yl]-5-ethylthiophen-2-yl}carbonyl)amino]-3,3-difluorocyclohexyl]carbamate(1314894-25-1)
• EPA Substance Registry System: tert-butyl [(1R,2R)-2-[({4-[6-(difluoromethoxy)pyrazolo[1,5-a]pyrimidin-3-yl]-5-ethylthiophen-2-yl}carbonyl)amino]-3,3-difluorocyclohexyl]carbamate(1314894-25-1)

Safety Data

• Hazardous Substances Data: 1314894-25-1(Hazardous Substances Data)

Upstream product

• 1314893-97-4 3-bromopyrazolo[1,5-a]pyrimidin-6-ol 
• 1314893-98-5 3-bromo-6-(difluoromethoxy)pyrazolo[1,5-a]pyrimidine 
• 1314893-89-4 tert-butyl (1R,2R)-2-({[5-ethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)thiophen-2-yl]carbonyl}amino)-3,3-difluorocyclohexylcarbamate 
• 1314893-87-2 tert-butyl (1R,2R)-2-{[(4-bromo-5-ethylthiophen-2-yl)carbonyl]amino}-3,3-difluorocyclohexylcarbamate 
• 55405-68-0 3,6-dibromopyrazolo[1,5-a]pyrimidine 
• 1109284-37-8 tert-butyl N-[(1R,2R)-2-amino-3,3-difluorocyclohexyl]carbamate 
• 40477-61-0 5-ethyl-4-bromo-thiophene-2-carboxylic acid 

Downstream Products

• 1314893-44-1 N-[(1R,6R)-6-amino-2,2-difluorocyclohexyl]-4-[6-(difluoromethoxy)pyrazolo[1,5-a]pyrimidin-3-yl]-5-ethylthiophene-2-carboxamide 

Relevant articles and documents

PYRAZOLO[1,5-A]PYRIMIDINES AS MARK INHIBITORS

The invention encompasses pyrazolo[1,5-a]pyrimidine derivatives which selectively inhibit microtubule affinity regulating kinase (MARK) and are therefore useful for the treatment or prevention of Alzheimer's disease. Pharmaceutical compositions and methods of use are also included.